These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 32654378)
21. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678 [TBL] [Abstract][Full Text] [Related]
22. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146 [TBL] [Abstract][Full Text] [Related]
23. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778 [TBL] [Abstract][Full Text] [Related]
24. Is a "Cytokine Storm" Relevant to COVID-19? Sinha P; Matthay MA; Calfee CS JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883 [No Abstract] [Full Text] [Related]
29. A plea for the pathogenic role of immune complexes in severe Covid-19. Vuitton DA; Vuitton L; Seillès E; Galanaud P Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273 [No Abstract] [Full Text] [Related]
30. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Schijns V; Lavelle EC Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684 [TBL] [Abstract][Full Text] [Related]
32. Treating COVID-19 with colchicine in community healthcare setting. Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478 [No Abstract] [Full Text] [Related]
33. The Inflammasome in Times of COVID-19. de Rivero Vaccari JC; Dietrich WD; Keane RW; de Rivero Vaccari JP Front Immunol; 2020; 11():583373. PubMed ID: 33149733 [TBL] [Abstract][Full Text] [Related]
34. Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on. Lipworth B; Chan R; Kuo CR Ann Allergy Asthma Immunol; 2020 Nov; 125(5):503-504. PubMed ID: 32585180 [No Abstract] [Full Text] [Related]
35. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Wu D; Yang XO J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092 [TBL] [Abstract][Full Text] [Related]
36. Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. Hajivalili M; Hosseini M; Haji-Fatahaliha M Life Sci; 2020 Sep; 257():118058. PubMed ID: 32653518 [TBL] [Abstract][Full Text] [Related]
37. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322 [TBL] [Abstract][Full Text] [Related]
38. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic. Bishop MR Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251 [No Abstract] [Full Text] [Related]
39. COVID-19: Some clinical questions after the first 4 months. Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550 [No Abstract] [Full Text] [Related]